Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat


Why You Don't See Ads on GreenMedInfo

Did you know that GreenMedInfo.com is 100% member supported? It is through your membership that we are able to add research content daily, provide thoughtful articles on groundbreaking health & wellness topics, and continue to educate and empower people on the science supporting natural healing.

Our website has always offered open access to our carefully curated research (and always will) but we recently made the decision to become completely advertisement free.

In order for us to continue, we need your support more than ever. Our memberships start at only $8.00 per month and provide you with enhanced content & features.

We appreciate you supporting our mission and sharing our passion!

For more information on becoming a member of GreenMedInfo.com, click here.

Abstract Title:

Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.

Abstract Source:

Oncol Rep. 2000 Nov-Dec;7(6):1299-304. PMID: 11032933

Abstract Author(s):

Y Murata, Y Ogawa, T Saibara, A Nishioka, Y Fujiwara, M Fukumoto, T Inomata, H Enzan, S Onishi, S Yoshida

Article Affiliation:

Department of Radiology, Kochi Medical School, Oko-cho, Nankoku 783-8505, Japan. muratay@kochi-ms.ac.jp

Abstract:

Adjuvant tamoxifen has become the treatment of choice against estrogen receptor-positive breast cancer. Adverse effects are rarely observed and since symptoms of hepatic steatosis, non-alcoholic steatohepatitis and cirrhosis are usually negligible, such effects are not well characterized despite large cohort studies of adjuvant tamoxifen. This issue remains to be systematically studied. The present study consisted of 136 breast cancer patients treated with or without tamoxifen. Patients had laboratory tests once each month and underwent abdominal computed tomography (CT) annually for 5 years. The extent of hepatic steatosis was assessed by CT as the liver/spleen ratio. While receiving adjuvant tamoxifen, 40 of 105 patients developed hepatic steatosis (liver/spleen ratio<0.9) without obvious changes in body mass index. Twenty-one had a liver spleen ratio of<0.5, whereas none of the 31 patients treated without tamoxifen had a ratio<0.9 or<0.5 (p<0.0001 and p<0.0001, respectively). Hepatic steatosis was recognized in 35 of the 40 patients within the first 2 years of receiving adjuvant tamoxifen and 21 of the 40 had increased transaminase levels. Liver biopsy revealed NASH in 6 of 7 patients among the 21 with a liver/spleen ratio of<0.5. A subset of individuals given adjuvant tamoxifen developed progressive hepatic steatosis without significant changes in the body mass index. We suggest a liver/spleen ratio of<0.5 as a criterion upon which liver biopsy should be recommended since NASH frequently occurred in such patients.

Study Type : Human Study

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get two FREE E-Books

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Depression: 21st Century Solutions + The Dark Side of Wheat

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2018 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.